A phase Ib, open-label, multicenter trial of intravenous INO-1001 plus oral temozolomide to evaluate the tolerability, safety, and pharmacokinetics in subjects with newly-diagnosed or recurrent unresectable stage III or stage IV melanoma
Phase of Trial: Phase I/II
Latest Information Update: 27 Nov 2014
At a glance
- Drugs INO 1001; Temozolomide
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Genentech
- 09 Mar 2009 Status changed from active, no longer recruiting to discontinued, according to ClinicalTrials.gov.
- 13 Jan 2006 New trial record.